Abstract
In the last decade radiotracers have been gradually growing in importance as aids for the development of new drugs. This development has been most pronounced for Psychiatric and Neurologic drugs [1, 2], but has more recently been adapted to the development of drugs against cancer. In this mini-review, we describe how advances in molecular imaging of cancer are likely to lead to advances in development and improved application of anti-cancer drugs [3]. We will focus on 4 aspects of use of radiotracers: 1) for treatment response assessment; 2) for the study of kinetics and pharmacology of novel drugs, including bioavailability and local tumor concentration; 3) the identification of the biologic target at the cellular level; 4) the combination of nanocarriers and radioisotopes to improve biodistribution.
Keywords: Drug Development, radiotracers, molecular imaging, anti-cancer drugs, Cancer Biology
Current Pharmaceutical Design
Title: Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Volume: 15 Issue: 9
Author(s): Steven M. Larson
Affiliation:
Keywords: Drug Development, radiotracers, molecular imaging, anti-cancer drugs, Cancer Biology
Abstract: In the last decade radiotracers have been gradually growing in importance as aids for the development of new drugs. This development has been most pronounced for Psychiatric and Neurologic drugs [1, 2], but has more recently been adapted to the development of drugs against cancer. In this mini-review, we describe how advances in molecular imaging of cancer are likely to lead to advances in development and improved application of anti-cancer drugs [3]. We will focus on 4 aspects of use of radiotracers: 1) for treatment response assessment; 2) for the study of kinetics and pharmacology of novel drugs, including bioavailability and local tumor concentration; 3) the identification of the biologic target at the cellular level; 4) the combination of nanocarriers and radioisotopes to improve biodistribution.
Export Options
About this article
Cite this article as:
Larson M. Steven, Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787581959
DOI https://dx.doi.org/10.2174/138161209787581959 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Role of Inflammation and Tumor Microenvironment in the Development of Gastrointestinal Cancers: What Induced Pluripotent Stem Cells Can Do?
Current Stem Cell Research & Therapy The Adrenergic System in Gastrointestinal Cancers
Current Cancer Therapy Reviews Proteomic Study of the Mechanism of Talin-C as an Inhibitor of HIV Infection
Current Proteomics Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Invasive Aspergillosis: Focus on New Approaches and New Therapeutic Agents
Current Medicinal Chemistry - Anti-Infective Agents Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Oxidative Stress and Cellular Senescence: The Key Tumor-promoting Factors in Colon Cancer and Beneficial Effects of Polyphenols in Colon Cancer Prevention
Current Cancer Therapy Reviews PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
Current Medicinal Chemistry DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA When Does Food Refusal Require Professional Intervention?
Current Nutrition & Food Science